Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium to Prevent Cisplatin-Induced Nephrotoxicity in Head and Neck Cancer
NCT05586009Phase 2Completed
- Sponsor
- Tanta University
- Start
- Oct 2022
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of magnesium in cisplatin-induced nephrotoxicity (CIN), sponsored by Tanta University. Started Oct 2022; status: completed.
02
Drugs
magnesium
03
Conditions
cisplatin-induced nephrotoxicity (CIN)
Beyond the preview
Go deeper on NCT05586009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586009.